Global Bone Graft Substitutes Market Companies
- Arthrex, Inc.
- Baxter International Inc.
- Johnson & Johnson (DePuy Synthes)
- Medtronic Plc.
- Integra LifeSciences Holdings Corporation
- Musculoskeletal Transplant Foundation
- Stryker Corporation
- Wright Medical Group N.V.
- NuVasive, Inc.
- Zimmer Biomet Holdings, Inc.
Recent News:
- In March 2022, Biocomposite signed an agreement with Zimmer Biomet to distribute Genex Bone Graft Substitute. It is an extremely pure biphasic mixture created to achieve the ideal balance between the strength of the bone conductive scaffold and the persistence in the body to regenerate bone structure.
- In March 2022, Molecular Matrix, Inc. has launched Osteo-P synthetic bone graft substitute (BGS) for use in the musculoskeletal system. Osteo-P BGS was developed using the hyper-cross-linked carbohydrate polymer (HCCP) technology platform developed by Molecular Matrix, which is designed to optimize the microenvironment for bone repair and regeneration.
- In February 2022, Orthofix Medical launched its synthetic bioactive bone graft solution, Opus BA, an autogenous bone marrow hydrated bone graft solution or saline autograft, for appropriate procedures. Especially the cervical and lumbar spine. This solution can be used to fill gaps or voids in the bones of the skeletal system and is available in putty and strip form.
- In August 2021, Karolinska Development launched OssDsign Catalyst, a synthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries in the United States. The launch will likely help the company gain a foothold in the bone graft market, the largest geographic market for medical device innovation.
- In January 2021, Dentsply Sirona announced acquisition of Datum Dental Ltd. With this acquisition, the company will promote the complete OSSIX portfolio, including OSSIX Plus, OSSIX Volumax and OSSIX Bone in the United States, Canada and several other countries.